---
title: "OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director | OKYO Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293486768.md"
description: "OKYO Pharma announced that Gary S. Jacob, Chief Development Officer and Director, purchased 3,500 ordinary shares at $1.40 per share on NASDAQ. This transaction increased his total holdings to 112,420 shares."
datetime: "2026-07-22T06:00:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293486768.md)
  - [en](https://longbridge.com/en/news/293486768.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293486768.md)
generator: "portal-rs"
---

# OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director | OKYO Stock News

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Gary S. Jacob, PhD, Chief Development Officer and Director of OKYO Pharma has increased his holdings with the purchase of 3,500 of the Company’s ordinary shares on NASDAQ at $1.40 per share, bringing his total holding to 112,420 ordinary shares.

**About OKYO** **Pharma** 

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

**For further inquiries:**

**OKYO Pharma Ltd**  
Paul Spencer  
Business Development and Investor Relations  
+44 (0) 207 495 2379  
Email: info@okyopharma.com

### Related Stocks

- [OKYO.US](https://longbridge.com/en/quote/OKYO.US.md)

## Related News & Research

- [OKYO Pharma Files Annual Report and Secures Funding for Phase 3 NEPTUNE Trial](https://longbridge.com/en/news/293213635.md)
- [OKYO Pharma Director Ups Stake Ahead of Planned Phase 3 Neuropathic Corneal Pain Trial](https://longbridge.com/en/news/293646761.md)
- [Nuclear material found in Syria will remain in the country, minister says](https://longbridge.com/en/news/296240603.md)
- [OKYO Pharma chairman raises stake to 20.51% after buying 25,000 shares at $ 1.4](https://longbridge.com/en/news/293329898.md)
- [OKYO Pharma Executive Boosts Shareholding Ahead of Planned Phase 3 NCP Trial](https://longbridge.com/en/news/293487942.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**